Stay updated on Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Record History now displays additional version entries with updated timestamps, while core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-03T09:57:14.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    31 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding lapse notice and confirms the NIH Clinical Center is open, with status sources listed, and a version upgrade to v3.2.0.
    Difference
    8%
    Check dated 2025-10-05T14:26:04.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Version bump from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.2%
    Check dated 2025-09-28T09:46:28.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Revision updated to v3.0.2; Back to Top element removed. Core content and key data remain unchanged.
    Difference
    0.5%
    Check dated 2025-09-14T00:16:03.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.5%
    Check dated 2025-09-06T21:04:45.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries. These changes enhance the clarity and relevance of the page's content.
    Difference
    76%
    Check dated 2025-08-30T15:27:34.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in TKI-Resistant EGFR-Mutated NSCLC Clinical Trial page.